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INTRODUCTION 
Hemoglobinopathies are among the most common monogenic disorders in the world and it is 
estimated that about 1.5% of the global population (80 to 90 million people) are carriers of β-
thalassemia. The total annual incidence of symptomatic individuals is estimated at 1 in 100,000 
throughout the world and 1 in 10,000 people in the European Union. 1 
β-thalassemia is prevalent in populations in the Mediterranean, Middle East, Transcaucasus, Central 
Asia, Indian subcontinent, and Far East. It is also common in populations of African heritage. The 
highest incidences are reported in Cyprus (14%), Sardinia (10.3%), and Southeast Asia. The 
frequencies of β-thalassemia are particularly high in the malarial tropical and sub-tropical regions of 
Asia, Mediterranean and the Middle East, because of a selective advantage of heterozygotes against the 
severe forms of malaria.2 However, because of population migration β-thalassemia  is now also 
common in northern Europe, North and South America, the Caribbean, and Australia.3  
Nowadays, in the less developed countries, affected children are on the increase due to falling 
childhood mortality from improved nutrition and better infection control, while in the more developed 
countries, epidemiology of the disease has been affected by a fall in total birth rate and preventive 
programs.  
Carriers (heterozygotes) of β-thalassemia  are clinically normal and largely unaware of their genetic 
condition. Inheritance of two copies of β-thalassemia  genes, one from each parent, usually results in 
life-threatening anemia and transfusion-dependence for survival. Intermediate clinical forms of the 
disease exist as thalassemia intermedia, which is characterized by moderately severe anemia with the 
occasional need for blood transfusion. The mainstay of treatment for the severe forms (thalassemia 
major) is blood transfusion and aggressive management of complications including life-long iron 
chelation therapy.  
The complications of iron overload, together with the sequels of the anemia and ineffective 
erythropoiesis, and the chelation therapy itself, are major causes of morbidity and mortality in the 
transfusion dependent β-thalassemias.4 Although, regular blood transfusions in combination with 
aggressive iron chelation have been remarkably effective in delaying the onset of iron-related organ 
failure and improving mortality, many patients continue to be affected by cardiac disease, delayed 
pubertal maturation, and develop endocrine failure.5 Further, the commitment to this rigorous life-
long treatment regime is onerous and an enormous imposition on quality of life.  
Hence, the continuing quest is for a molecular-based strategy, which, at best, will lead to a cure, and, at 
the very least, can ameliorate the anemia in the severe transfusion-dependent β-thalassemias. To this 
regard recent advances in the understanding of γ gene expression mechanisms bring hope. However, 
much has still to be done to better define the overall molecular basis of β-thalassemia. Such knowledge 
could not only bring to a molecular-based strategy but also improve the prediction of the phenotype 
from genotype in the prevention and management of β-thalassemia or even other genetic diseases. 
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BACKGROUND 
β-thalassemias (OMIM 141900) are a heterogeneous group of autosomal recessive disorders 
characterized by reduced (β+) or absent (β°) production of adult hemoglobin A (α2β2) β-globin chains. 
The main pathophysiologic mechanism is the imbalance between α and non α-globin chains: the non 
assembled α-globin chains precipitate in the form of inclusions. These α-globin chain inclusions 
damage the erythroid precursors in the bone marrow and in the spleen, causing ineffective 
erythropoiesis. More than 200 mutations of different severity have been described in the β-globin 
gene.6-8 The wide variability of globin chain imbalance in homozygous β-thalassemia result in a wide 
spectrum of clinical manifestations, ranging from thalassemia major to thalassemia intermedia. 
Thalassemia major patients have a very severe anemia from early infancy, which needs lifelong blood 
transfusions. On the other hand thalassemia intermedia patients have a less severe anemia and survive 
without transfusions or with sporadic transfusions.  
Since the key factor for the severity of β-thalassemia is the imbalance between α and non α-globin 
chains, any determinant able to reduce this imbalance is expected to produce a milder clinical 
phenotype. Mechanisms so far identified as responsible of thalassemia intermedia are: 
a) presence of mild or silent β+-thalassemia mutations with consistent residual production of β-globin 
chains (and hence HbA), and reduced excess of free α chains. Mild or silent β+-thalassemia mutations 
are some transcriptional mutants (i.e. –101 CT; -87 CG; -30 TA), some mutations activating 
alternate splice sites (i.e. cd 19 AG; cd 24 TA), some mutations in the consensus sequences (i.e. IVS 
1-6 TC; IVS2-844 CG) and polyadenilation mutations; 
b) co-inherited α thalassemia defects, able to consistently reduce the α-globin chain excess present in 
β-thalassemia patients. The ameliorating clinical effect of co-inherited α thalassemia is more 
predictable in presence of β+-thalassemia mutations, while in homozygous β°-thalassemia patients 
producing only HbF, even the coinheritance of two α-globin gene deletion not always results in a mild 
phenotype; 
c) co-transmitted determinants increasing the γ chain production and hence HbF (α2γ2). These 
determinants may be related to the nature of the thalassemia mutation itself, such as δβ°-thalassemias 
caused by deletions of variable size in the β-globin cluster and some rare β°-thalassemia deletions 
extending into the β-globin promoter. Single point mutations of the hemoglobin Gγ (HBG2) or 
hemoglobin Aγ (HBG1) gene promoter can also be responsible of increased HbF production, the most 
common being a single-base substitution C to T at position 158 upstream of the transcription start site 
of the HBG2 gene, which is silent in normal individuals and in β-thalassemia heterozygotes, but leads 
to increased HbF production in individuals with erythropoietic stress, as occurs in homozygous β-
thalassemia. This HBG2 mutation, sometimes referred to as Gγ-158 C>T is in linkage disequilibrium (in 
cis configuration) with some β-globin gene mutations.  
Co-inherited determinants increasing HbF may or may not be linked to the β-globin gene cluster, such 
as the non deletion hereditary persistence of fetal hemoglobin. Recent studies using genome-wide 
association studies (GWAS) have identified quantitative trait loci (QTLs) independent from the β-
globin gene cluster and it is likely that many other HbF-associated QTLs also exist.  
In humans, a shift from γ to β-globin gene expression around birth, underlies the switch from fetal to 
adult hemoglobin production such that by six months of age, the major hemoglobin is HbA (α2β2).9 
However, residual amounts of HbF continue to be synthesized throughout adult life and the 
continuous distribution of HbF trait suggests it is a quantitative trait, accounting in adults for <1% of 
total hemoglobin.10 Its persistence in adult life is highly variable and genetically controlled with a 
heritability of 0.89.11 Pancellular forms of hereditary persistence of fetal hemoglobin (HPFH) are 
relatively rare, while surveys of HbF distribution in normal individuals suggest that heterocellular 
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forms (hHPFH), defined as HbF levels between 0.8% and 5%, may be present in about 10% of the 
population.12,13 
All β-thalassemias have variable increases in HbF, but one extreme form can be observed in β°-
thalassemia intermedia patients who are transfusion independent with a mild disease despite the 
absence of HbA.14-17 In the majority of β-thalassemia a large part of the HbF response is related to the 
erythropoietic stress, expanded erythroid mass, and preferential survival of the red cell precursors 
that contain HbF. Still, as previously mentioned, studies on the interaction of hHPFH with β-
thalassemia suggested that the high HbF determinant can be linked to the β-globin locus, or can 
segregate independently implicating trans-acting QTLs.14,18-23 
To date, three major loci that modulate HbF levels have been identified – Xmn1-HBG2 on 11p15.4, 
HBS1L-MYB intergenic region on 6q23.3, and BCL11A on 2p16.1 – contributing to 20–50% of the trait 
variance in patients with β-thalassemia, sickle cell disease and in healthy European Caucasians.24-42 In 
the HBS1L-MYB locus it seems that MYB is causally involved through alteration of erythroid kinetics, 
while BCL11A has shown to act together with SOX6 via direct transcriptional repression of the γ-
globin genes and to be activated by KLF1, whereas GATA-1 has shown to be a widespread and general 
regulator of transcription in erythroid cells that binds to α and β-globin as well as to HBS1L-MYB and 
BCL11A loci.25,43-48 However, evidence exist for other contributing loci as the 8q and Xp22.2–22.3 QTLs, 
but were not validated in recent GWAS that mainly studied moderately raised levels of HbF.49-53 
In addition, other determinants than HbF levels might contribute to the phenotypic severity of β-
thalassemia, through the coinheritance of other genetic factors mapping outside the β-globin gene 
cluster (the best known example being UGT1A: its mutation causing Gilbert disease leads to increased 
jaundice and increased risk of gallstones in thalassemic patients).54 A part of the still unexplained 
phenotypic variation probably involves the proteolytic capacity of the erythroid precursors in 
catabolizing the excess α-globin chains and the destruction mechanisms of red cell progenitors and 
their progeny, including mechanical damage, interference with cell division and oxidative destruction 
of both organelles and components of the red cell membrane.55 The nitric oxide depletion from chronic 
hemolysis together with abnormal red blood cell (RBC) phospholipid membrane asymmetry might 
also be related to the pathogenesis of hypercoagulability, a chronic condition of thalassemic patients 
that also involves platelets, endothelial cells, monocytes and peripheral blood activation.56,57   
In summary, while the genetic determinants of β+-thalassemia phenotypic variations have been largely 
defined, the inherited modifying factors able to ameliorate the clinical features in the majority of 
patients with β°-thalassemiahave been only partially clarified yet. In fact, the presence of mild or silent 
β+-thalassemia defects, with a relatively high residual output of β-globin synthesis, is adequate to 
produce a mild clinical picture. The coinheritance in these patients of α thalassemia, additionally 
reducing the α/non-α imbalance, further ameliorates the clinical phenotype. On the other hand, the 
molecular basis of β°-thalassemia has greatly benefited from recent studies on genetic determinants of 
HbF levels, but the variation of disease severity is still not fully understood.  
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AIM, RATIONAL AND HYPOTHESIS 
AIM 
The goal of this study is to identify and characterize new candidate modifier genes which are effective 
in ameliorating the clinical phenotype of β°-thalassemia patients. Knowledge of the control of 
developmental expression of these genes may lead to targeting specific modifiers in order to correct or 
moderate the effect of α/non-α chains imbalance, to decrease clinical severity in patients with β-
thalassemia and sickle-cell anemia. 
RATIONALE 
All subjects included in the study are homozygous for the 39 C->T mutation, with no residual 
production of β chains and all negatives for the Gγ-158 C>T mutation. Still, patients with thalassemia 
major are lifelong dependent on blood transfusion (transfusion dependent – TD) while patients with 
thalassemia intermedia can survive without transfusion (non transfusion dependent – NTD). In this 
last category of patients, the amount of γ chains necessary to reduce the α chains excess (and the 
ineffective erythropoiesis) through formation of α2 γ2 tetramers (HbF) should be elevated. These 
patients are able to maintain a hemoglobin levels of 7 to 11 g/dl without red blood cell transfusions 
and their hemoglobin is composed of only HbF and traces of HbA2.  
Therefore, some determinants exist that are responsible for the difference between TD and NTD 
patients and should strongly affect HbF levels. However differences, mostly within TD group, make 
this separation less evident: some TD patients might start transfusion at birth whereas others might 
start blood transfusions after years. Furthermore, for some TD patients, decision to start transfusion 
could have been required by temporary environmental factors but conduced to transfusion 
dependency and TD status. Hence it could be more appropriate to study the time to first transfusion 
than the TD status for two reasons: first because it should be more accurate, defining both TD/NTD 
group membership and within groups differences, and second because it should allow an analysis of 
other factors than HbF levels also responsible for phenotype amelioration. 
The considered population represents a unique model to study genes ameliorating the severe 
phenotype of homozygous β°-thalassemia, and eventually uncover loci contributing to HPFH for which 
evidences exist but were not yet validated in recent GWAS, as the 8q and Xp22.2–22.3 QTLs.49-53 In 
particular, the linkage to the chromosome Xp22.2–p22.3 locus was identified in a population 
associated with the inheritance of an extreme high fetal cells trait and early studies of families with 
sickle cell disease suggested high HbF determinants that segregated independently of the β-globin 
locus.58 It is therefore conceivable that this finding represent linkage to a form of HPFH not 
represented in subsequent studies to date, as recent GWAS investigated levels of moderately “raised” 
HbF or with microarrays scarcely covering the X chromosome.24,59-62 Besides HbF levels, many other 
factors responsible for amelioration for the phenotype of homozygous β°-thalassemia are still to be 
discovered, as any element inducing better survival of red blood cells, normally making no difference 
to healthy subjects, could allow β°-thalassemia patients to start later or never start transfusions. 
We therefore propose in the present study to perform a whole genome scan using hybrid technology 
to test for association of time to first transfusion with SNPs and association of TD status with rare 
CNVs, linked to genes or gene pathways that contribute to severity of homozygous β°-thalassemia 
phenotype. We used the Affymetrix Gene Chip Mapping 6.0 microarray, an assay that enables highly 
representative genome-wide coverage of SNPs and extensive coverage of known CNVs and 
polymorphic regions of the genome. We took advantage of the existence of a unique and homogeneous 
group of 386 Sardinian patients, all homozygous for the 39 C->T mutation and followed at the 
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Ospedale Microcitemico di Cagliari, to try to uncover independent SNPs and rare CNVs representing 
genes or candidate regions associated with the modulation of homozygous β°-thalassemia phenotype. 
HYPOTHESIS 
The main hypothesis assumed in the present study are the following: 
- Time to transfusion is a phenotype able to reflect correctly the underlying endophenotypes 
that are HbF levels and other elements eventual contributing to the variation of time to first 
transfusion. 
- TD versus NTD is a phenotype able to reflect correctly the underlying endophenotypes that are 
HbF levels and other elements eventual contributing to the variation of time to first 
transfusion. 
- Some loci influencing β°-thalassemia phenotype are yet to discover. 
- SNPs and/or CNVs are relevant to identify such loci. 
- CNVs influencing TD status are rare. 
- The effects of such loci are important enough. 
Regarding the last point, according to the power estimation used to plan our study, under the additive 
model, we have ≥ 70% power for detecting variants with genetic relative risk ≥ 4 over a wide range of 
allele frequencies (MAF ≥ 0.19), down to a genetic relative risk of 3.4 for a MAF of 41% . The estimated 
power was calculated for a GWAS of 59 cases and 327 controls with an overall p-value of 1.00E-07 
(corresponding to a genome-wide significance level of 0.05 after a stringent Bonferroni correction for 
multiple testing of 500,000 independent SNPs) using Quanto software.63 This hypothesis is the most 
stringent that we used (gene based joint testing SNP analysis for TD status, see results), however the 
power of the present analysis was increased by our choice to use survival analysis for SNP analysis. 
Regarding CNV analysis, we reduced greatly the burden of markers using only consensual CNVs among 
different algorithms.  
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METHODOLOGY 
PATIENTS 
The following patients were studied: 59 patients with β°-thalassemia intermedia and 327 with 
thalassemia major with the same -globin gene mutation (homozygotes for the 39 C->T mutation). 
This population is composed of 386 founders from Sardinia, all negative for the Gγ-158 C>T mutation, 
divided in 201 males and 185 females. 
In Sardinia about 10% of patients homozygotes for β° 39 CT non-sense mutation, have the mild 
clinical phenotype of β°-thalassemia intermedia. These patients are able to maintain a hemoglobin 
levels of 7 to 11 g/dl without red blood cell transfusions (i.e.: non transfusion dependent patients - 
NTD) and their hemoglobin is composed of only HbF and traces of HbA2. This population of patients 
represents a unique model for studying the effect of genes able to ameliorate the severe clinical 
phenotype of homozygous β°-thalassemia. 
All patients are from Sardinia, an island at least geographically “distinct” and therefore less susceptible 
to genetic admixing. Consequently, influx of different mutations on different haplotype backgrounds 
causing the same phenotype should be minimized, making this population ideal for the study.  
For each patient the following information were available:  
- gender; 
- age at first transfusion or age at last follow-up; 
- 39 C->T mutation status (all patients are homozygotes for such mutation); 
- co-inherited α thalassemia defects. 
Table 1. Characteristics of the studied population. 
Gender 
(Number of cases) 
Males 201 
Females 185 
Alpha thalassemia defects 
(Number of cases) 
-α/-α 41 
-α/αHphIα 1 
-α/αNcoIα 5 
-α3,7/-α4,2 2 
-α/αα 113 
-α4,2/αα 2 
αHphIα/αα 2 
αNcoIα/αα 13 
-α/ααα 1 
αα/αα 204 
ααα/αα 2 
Age at first transfusion 
[TD patients] 
Median = 8 months 26 days 
IQR = 1 year 3 months 
Age at last follow-up 
[NTD patients] 
Mean = 41 years 3 months 
Std. Dev. = 12 years 
 
All participants enrolled were volunteers who signed an informed consent after detailed explanations 
on the purpose and modalities of the study project. 
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PROTOCOL 
The study consisted in a whole genome scan on 386 samples to test for association between time to 
first transfusion and SNPs and between TD status and rare CNVs, to find genes or candidate regions 
that contribute to the amelioration of homozygous β°-thalassemia phenotype.  
We performed such hybrid technology GWAS using the Affymetrix Gene Chip Mapping 6.0 microarray, 
that consists of about 906,600 SNPs sequences and about 900,000 non polymorphic oligonucleotides, 
covering the whole genome with an average spacing of 0.7 Kb (Affymetrix, Santa Clara, CA, USA). To 
such purpose we digested genomic DNA (250 ng) in 2 separate reactions with Nsp I or Sty I (New 
England Biolabs, Ipswich, MA, USA), as recommended by the manufacturer (Affymetrix). Following 
digestion, an adaptor was linked to the restricted fragments, the reaction diluted 4X and the fragments 
amplified by PCR. After purification using Magnetic Beads (Agencourt Bioscience Corporation, Beverly, 
MA, USA), 90 μg of PCR products were fragmented and end labeled using 30 U/μl of terminal 
deoxynucleotidyl transferase, and then hybridized for 16-18 hours to the Affymetrix 6.0 chip at 490 C 
in the Gene Chip Hybridization Oven 640 (Affymetrix). Chips were washed, stained in the GeneChip 
Fluidic Station 450 and scanned with the Scanner 3000 7G (Affymetrix). 
Successively Affymetrix CEL files were loaded into the proprietary software Genotyping Console (GTC) 
v. 4.0 (Affymetrix) for genotype and copy number analysis. The Birdseed v. 2.0 genotype calling 
algorithm was used to perform a multiple-chip analysis to estimate a signal intensity for each allele of 
each SNP, fitting probe-specific effects to increase precision. It then made genotype calls by fitting a 
Gaussian mixture model in the two-dimensional A signal versus B signal space, using SNP specific 
models to improve accuracy. Copy number analysis was performed with GTC v. 4.0 using the 
Affymetrix HapMap270 reference model file for comparison, while segmentation was also performed 
using two other algorithms (PENNCNV and QUANTISNP) to obtain a pool of consensual segments from 
which we analyzed rare CNVs.64-67 
Genome-wide analysis of SNP frequencies were implemented using PLINK v1.07 and R v. 2.9.2, after 
imputation on CEPH (Utah residents with ancestry from northern and western Europe - CEU) plus 
Tuscany (Italians from Toscana - TSI) samples from The International HapMap Consortium, using 
MACH v.1.0.16 software.68-71 Prior to imputation, quality control procedures were implemented to 
remove “failed calls markers”. We excluded samples with low call rates, samples from related subjects 
or indicating eventual contamination or replication through identity by state analysis, and samples 
with discrepancies between gender and computed sex. We also checked for samples with inbreeding 
coefficient indicating possible contamination or outliers at nearest neighbor analysis and for outliers 
at principal component analysis (PCA) using the software package EIGENSTRAT.72 We flagged SNPs for 
low genotype call rate, low minor allele frequency and failure of Hardy-Weinberg equilibrium. 
Association with time to first transfusion was done through survival analysis using a Cox proportional 
hazards model. SNPs with association p-values less than 1.00E-07 were considered statistically 
significant. 
For CNV analysis, intensity signals of samples were treated using GTC v. 4.0 to produce quality control 
indexes specific to CNV analysis process. We filtered out samples improper for analysis and corrected 
signals using the median of the absolute values of all pairwise difference (MAPD), regional GC 
correction and the number of CNVs per sample. Then, we performed copy number segments analysis 
using GTC v. 4.0 as well as two other segmentation algorithms (PENNCNV and QUANTISNP) to select 
CNVs found in at least two of the three different segmentation algorithms. Settings were identical for 
all three algorithms, considering a minimum of 5 markers showing consensus for gain or loss spanning 
at least a 100 kb region. To consider only rare CNVs, all CNVs present in more than 1% of TD samples 
were eliminated from further analysis. We then ran analysis on the remaining CNVs to check 
association with TD status: case/control analysis for association with the phenotype was done using 
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permutation procedures made available in PLINK v. 1.07.73 Each rare copy number containing known 
genes or small RNA sequences resulting significant at genome-wide level were considered.  
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RESULTS 
QUALITY CONTROL 
CNVs 
Copy number analysis, using the Affymetrix HapMap270 reference model file for comparison, was 
performed using GTC v. 4.0 (Affymetrix). The median of the absolute values of all pairwise difference 
(MAPD) was used to evaluate whether the chip produced data useful for copy number analysis. MAPD 
is defined as the median of the absolute values of all pairwise differences between log2 ratios for a 
given chip and Affymetrix recommends that the MAPD value be less than 0.4. In addition, we removed 
samples outliers for the number of CNVs. 
Upon MAPD analysis and number of CNVs per sample, we removed 60 samples (11 NTD and 49 TD) 
for a remaining number of 326 samples (48 NTD and 278 TD). 
An important part of quality control for CNVs also relayed on the GC correction we applied and on the 
filtering of consensual CNVs from different segmentation algorithms that we performed. These 
techniques are detailed in the following sections. 
SNPs 
We excluded samples with low sample call rates (<97%) and discrepancies between referred and 
calculated sex. We also analyzed samples for their identity by state using GRR software to eliminate 
samples from related subjects or with eventual contamination or replication (see Figure 1).74 
Furthermore, we developed a composite index for samples with marginal call rate (between 97 and 
98.5%): for such sample we also considered the inbreeding coefficient (F) and the nearest neighbor 
score (Z) calculated with PLINK. We determined outlier samples for these two statistics and weighted 
samples call rate with their rank to obtain a composite index of these three measures, and eventually 
discard samples with marginal call rate and poor F or Z statistics. Finally we checked for outliers at 
principal components analysis (see next section) to eventually remove them, but no sample was above 
6 standard deviations. Table 2 and Table 3 summarize quality control procedures on samples and 
population characteristics. 
We also flagged SNPs for low SNP genotype call rate (< 98%), discrepancies in duplicate genotyping, or 
failure of Hardy-Weinberg equilibrium (HWE) (p-value <0.005). HWE test was conducted separately in 
NTD and TD patients using PEDSTATS.75 While deviation from HWE in cases may indicate association 
and, therefore, could help in the identification of disease variants, deviation from HWE in controls is 
often assumed to derive from genotyping errors, non random pattern of missing data, or unrecognized 
population stratification, so that we tested for HWE among control subjects for genotyping quality 
control. We also eliminated SNPs with minor allele frequency below 1% and SNPs with heterozygous 
genotypes while on haploid chromosomes. After quality control, overall genotype rate was: 0.997 for a 
total of 647,632 markers (see Table 4).  
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Table 2. Quality control procedures on samples. 
Quality control procedure 
Before 
QC 
Removed 
Left for 
analysis 
Call rate + inbreeding coefficient + nearest neighbor score 
386 
15 
345 
Sex discrepancies 11 
Identity by state 
15 
(8 twins/repeated + 
7 sibs/contaminated) 
 
 
Table 3. Characteristics of population before and after quality control. 
 Males Females NTD TD 
Before QC 201 184 59 327 
Left for analysis 178 167 48 297 
 
 
Table 4. Quality control procedures on SNPs. 
Quality control procedure 
Before 
QC 
Removed 
Left for 
analysis 
Call rate <0.98 
905,384 
138,637 
647,632 
Minor allele frequency < 0.01 119,245 
Test for Hardy Weinberg equilibrium, p-value < 0.005 8,195 
Heterozygous haploid genotypes 21,703 
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SEGMENTATION 
Segmentation is maybe the most important step of CNV analysis based on chips. However great 
variability is known to result from different segmentation algorithms.76 We therefore decided to 
concentrate on consensual CNVs using three algorithms, to reduce overall burden of CNVs and 
minimize false positive while maximizing true positives, based on the hypothesis that a CNV found by 
more than one algorithm has more chance to be reliable. We used, to this purpose, three software: the 
proprietary GTC v. 4.0 software (Affymetrix), PENNCNV and QUANTISNP.64-67 
After quality control (see before) and filtering of CNVs present in less than 1% of TD patients, we 
segmented intensity signal with a default setting of at least 5 markers showing consensus for gain or 
loss spanning at least a 100 kb region for all three algorithms. The burden of CNV found by each 
algorithm was quite different (9,490 for GTC, 3,934 for PENNCNV and 6,507 for QUANTISNP) so we 
decided to consider CNVs consensual in at least two of the three algorithms, not to give more 
importance to the algorithm finding less segments (in the case we would have chosen to only consider 
CNVs consensual in all three algorithms). 
To characterize consensual CNVs we used data management facilities for CNVs from PLINK v. 1.07 as 
well as ad-hoc UNIX syntax scripts and Excel spreadsheets (Microsoft Excel 2010, Microsoft, Redmond, 
Washington, USA).68 We first converted CNVs status in only one deletion and one duplication status 
and then collapsed CNVs from different algorithms together if they shared at least one probe, giving to 
the resulting CNV its limits from the minimum and maximum of both CNVs extremities. We decided 
not to consider different the CNVs overlapping for less than a certain threshold to be able to also 
include complex CNVs (i.e.: with borders not well defined between samples) in further analysis and 
because it represented a conservative approach, only adding more CNVs to the global burden of 
consensual CNVs we kept .  
We ascertained from such process that consensus between segmentation algorithms is low: GTC 
agreed with PENNCNV and QUANTISNP for 28% and 21% respectively (i.e.: 28% of CNVs found by 
GTC were also present in PENNCNV segmentation results), PENNCNV agreed with GTC and 
QUANTISNP for 68% and 39% respectively, and QUANTISNP agreed with GTC and PENNCNV for 30% 
and 24% respectively. PENNCNV specifically seems more sensitive but less specific, as its concordance 
rate is always higher but characterizing 2.5 and 1.7 times less CNVs than GTC and QUANTISNP 
respectively. However, even if concordance is scarce, among CNVs common between different 
segmentation algorithm a relatively high rate of physical overlap was found: 80% of CNVs we 
collapsed together shared more than 30% of their probes while 50% of them shared more than 70% of 
their probes (i.e.: probes identically assigned to a CNV as deletion or duplication by different 
segmentation algorithms), as shown on Figure 2. 
Comparing algorithms, only 7% of the total burden of CNVs was common at all three algorithms while 
18% of CNVs were found in at least two algorithms, corresponding to 35%, 74% and 34% of the 
respective totals of GTC, PENNCNV and QUANTISNP (see Table 5 and Figure 3). We developed our 
further analysis on these consensual CNVs. 
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Table 5. Percentage of CNVs common between different algorithms (percentages are referred to the 
total of the segmentation algorithm reported in column). 
 
GTC PENNCNV QUANTISNP 
GTC 100% 68% 30% 
PENNCNV 28% 100% 24% 
QUANTISNP 21% 39% 100% 
Consensual CNVs 35% 74% 34% 
Total number of CNVs 9490 3934 6507 
 
STRATIFICATION 
Spurious association may be obtained or true association overlooked if allele frequencies differ 
notably between subpopulations that are represented unequally between cases and controls due to 
systematic ancestry differences. Population structure needs to be assessed to make reliable 
conclusions in association studies.77-79 Most study designs propose sampling cases and controls from 
groups that share the same geographic origin or self-reported ethnic background, with the implicit 
assumption that no substructure exists within such groups. Results, however, indicate that analytic 
strategies need to take account of substructure as self-reported ethnicity is often inaccurate. Although 
we performed our initial analysis in reputed homogeneous population, we assessed for potential 
differences between cases and controls by measuring allelic frequencies of relatively common ethnic-
specific alleles using the Ancestry Informative Markers (AIMs) set and by principal component (PCA) 
analysis. Specifically, we used the PCA method by Price et al. as implemented in software package 
EIGENSTRAT to control for population stratification.80,81 This method enables detection and correction 
of population stratification on a genome-wide scale by using PCA to explicitly model ancestry 
differences between cases and controls. The resulting correction is specific to a candidate marker's 
variation in frequency across ancestral populations, minimizing spurious associations while 
maximizing power to detect true associations. This simple, efficient approach performs well under 
various situations including both discrete mixed populations and admixed populations and is more 
powerful than the genomic control approach and the STRUCTURE approach.82,83 
Our analysis resulted in ten significant principal components as calculated with twstats, however most 
of the variance was captured by the first four principal components (as upon the inflexion of 
eigenvalues scree plot). Correcting with these four will lead to acceptable correction in further 
analysis as shows the Q-Q plot on Figure 4. 
IMPUTATION 
Imputation of untyped SNPs was done using Mach v. 1.0.16 and a reference panel composed of CEPH 
and TSI samples from the Hapmap consortium.70  
After quality controls we carried out a two-step imputation process using the greedy option and 100 
rounds of iterations. In the first step a model is build that relates samples to the haplotypes in the 
reference panel and includes both an estimate of the "error" rate for each marker (an omnibus 
parameter which captures both genotyping error, discrepancies between typing platform and the 
reference panel, and recurrent mutation) and of "crossover" rates for each interval (a parameter that 
describes breakpoints in haplotype stretches shared between samples and the reference panel). In the 
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second step the parameters estimated in the first step are used to impute all SNPs in the reference 
panel in the sampled individuals. 
A third step of quality control consisted in removing all imputed SNPs that had a squared correlation 
with true genotypes below 0.30, to eliminate most of the poorly imputed SNPs but only a small 
number of well imputed ones. 
From 647,632 SNPs, we reached 1,413,093 SNPs after imputation, for a total genotyping rate of 0.957 
in 345 individuals. We could finally analyze a total of 1,253,352 SNPs (after filtering for squared 
correlation and MAF). 
For data management, we used the convert_mach.pl script from the GENGEN suite made available 
from the Open Bioinformatics software repository to reformat MACH imputed data.69,84 We included it 
in an extensive UNIX syntax script that performed overall imputation process, including strand 
flipping and verification through LD structure with the --flip-scan option in PLINK.73 The former 
process calculates the signed correlation between each SNP and a set of nearby SNPs in the reference 
and studied dataset separately to identify pairs of SNPs in which the absolute value of the genotypic 
correlation is above some threshold, so that counting the number of times the signed correlation is 
different in sign between the two datasets (a negative LD pair) versus the same (a positive LD pair) 
allows to finally eliminate outliers for such index. 
CORRECTION 
CNVs 
We applied regional GC correction to correct for the technical genome-wide artifact known as GC wave 
or waviness, which is a common, systematic issue observed with whole-genome assays. It corresponds 
to a spatial wave pattern in log2 ratios, exhibiting larger than expected variations of log2 ratios, that 
appears to be genome-wide or chromosome specific in some samples and is generally highly 
correlated with the GC content of the genomic region surrounding the probes.85,86 Data from literature 
and reported cases indicate that regions within the wave have an increased number of segments of 
copy number change and that these segments are longer than typical CN segments found in normal 
populations.86 Briefly, to apply GC correction, for each sample markers are divided into 25 bins based 
on the equally spaced percentiles of the average GC count (GC content)from 250 kb upstreamto250 kb 
downstream of a particular marker. For the autosomal markers in each bin, the median log2 ratio of 
each bin is adjusted to zero and interquartile ranges (IQRs) are equalized across all the bins. The IQRs 
of all the adjusted log2 ratios (including the X and Y chromosomes) are multiplied by a factor that 
makes the IQRs of the adjusted log2 ratios equal to the IQRs of the original log2 ratios. Finally, the log2 
ratios of all markers (including X and Y markers) in a bin are adjusted using the median of the medians 
of the log2 ratios for each autosome. 
SNPs 
For subsequent analysis we considered the following correctors in our model: the first 4 principal 
components, and imputation probability.  
Principal components were derived from the smartpca.perl and twstats scripts from the EIGENSTRAT 
v. 3.0 package, to respectively calculate principal components and determine their statistical 
significance, as described before. Imputation probabilities were derived from MACH v. 1.0.16 outputs, 
as described before.69,81 
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ASSOCIATION TESTING 
CNVs 
To consider only rare CNVs, all CNVs present in more than 1% of TD samples were removed from 
association testing analysis. Furthermore, testing the one-sided hypothesis of an increase of rare CNVs 
in NTD samples, we removed all CNVs non present in NTD samples. 
Case-control analysis for association with TD status was done using permutation procedures made 
available in PLINK v. 1.07.73 Permutation procedures have desirable properties such as relaxing 
assumptions about normality and providing a framework for correction for multiple testing, which 
drove our choice. 
Results of the analysis were visually checked using WGAVIEWER and compared against known copy 
number polymorphisms to further select interesting CNVs (containing known genes or small RNA 
sequences).87 
Association of rare CNVs with TD status was tested using 100,000 permutations, on the basis of 
markers as well as gene based (as upon the --cnv-test-regions commands in PLINK).73 The marker 
based analysis resulted in one duplicated region nearly significant at genome-wide level, while the 
gene based approach gave similar results (i.e.: first ranking genes were in the same regions as in the 
marker based analysis) but not genome-wide significant: genome-wide corrected p=0.075 (gw-p) with 
point-wise p=0.012 (pw-p) upon marker based analysis, and gw-p=0.469 with a pw-p=0.014 upon 
gene based analysis. This region, situated on chromosome 4 and spanning from 165.4 to 166.5 Mbp 
crosses the TRIM60, TRIM61 and KLHL2 genes. The signal in this region showed a coherent and well-
shaped duplicated signal in two NTD subjects, not present in TD subjects as shown on Figure 5, and 
was found by all three segmentation algorithms, with one segmentation algorithm even finding a 
scarce signal for an additional NTD patient as shown on Figure 6.  
SNPs 
Time to event was calculated as the time between birth and the first blood transfusion for each patient, 
if this occurred, for a lifelong period until last follow-up (January 2010). Predictive factors considered 
were gender, SNP genotype (coded as 0, 1 or 2 upon the number of copies of the minor allele, while 0 
and 1 for SNPs on X chromosomes for males) and imputation probability. 
Considering the longitudinal nature of the study, independent variables were entered into a Cox 
proportional hazards model to identify significant predictive factors for each outcome. Patients were 
considered uncensored when blood transfusion happened during the study (TD patients) and 
censored when blood transfusion did not happen (NTD patients). 
To do so we used the coxph() function from the R package SURVIVAL.71,88 In its basic form the coxph() 
model attempts to fit survival data with covariates z to a hazard function of the form: 
 ( | )    ( ) 
    
where β is an unknown vector and   ( ) is the non-parametric baseline hazard. To find the parameter 
β, the partial likelihood is solved in the form: 
 ( )   ∏
  
  ( )
∑   
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where (  )is the risk set at time   . 
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Given the estimate of β,  ̂ (a vector), along with the estimates’ covariance matrix,  ̂  ,  ̂    (   ̂  ) 
holds approximately since  ̂    as     and this approximation allows local tests to be done. A local 
null hypothesis can usually be put into matrix form,      where C is a q×p matrix of full rank and d 
is a vector of length q. Under this setup, the test statistic is: 
  
  (  ̂   ) [  ̂    ]
  
(  ̂   ) 
which under the null hypothesis follows   
  (this is the Wald test). 
Accordingly, the coxph() function includes in its summary: 
- estimates of the βk including standard errors and p-values for each test H0 : βk = 0 with the 
other     ̂ , 
- estimate of the risk ratio with confidence bounds, 
- p-values for likelihood ratio, Wald and score tests for the global null, H0 : βi= 0 for all i. 
We applied the coxph() function to our data through a R plugin for PLINK, and considered statistically 
significant all SNPs with p-values less than 1.00E-07 (corresponding to a genome-wide significance 
level of 0.05 after a Bonferroni correction for multiple testing of 500,000 independent SNPs).71,73 
The SNPs were then plotted in their genomic context using WGAVIEWER software, ordered upon their 
p-values and annotated against the last versions of genomic maps using ENSEMBL database (homo 
sapiens release 60, GRCh37).87,89 Finally a comprehensive annotation of surrounding SNPs with their 
respective LD measure was done, to assert the coherence of statistically significant signals. Figure 7 
gives an overview of results per chromosome.  
GENOME-WIDE SIGNIFICANT RESULTS 
Among genome-wide significant results (summarized in Table 6), the first one is BCL11A (most 
significant SNP: rs766432, p=2.24E-09), a well-known gene responsible of HbF production increase. 
Such result confirm the coherence of our approach and the effect of BCL11A not only on HbF 
production but as a major determinant of homozygous β°-thalassemia phenotype. The second ranking 
SNP, rs2541639, within HBM gene in the α-globin gene cluster is actually partially correlated to α gene 
deletions responsible for the observed phenotypic variation (see after for a detailed analysis of α-
globin gene cluster). The other gene significant at genome-wide level (PTPRD - rs7861848 with 
p=1,66E-08) is not known to influence HbF levels or β-thalassemia phenotype but encodes a protein 
tyrosine phosphatase, and members of this family are known to regulate a variety of cellular processes 
including cell-growth, differentiation, mitotic cycle and oncogenic transformation. However the SNP 
presents a low minor allele frequency (1%) and is isolated as all correlated SNPs were excluded for 
presenting even lower minor allele frequencies. This result is therefore not reliable. 
Table 6. Genome-wide significant results. 
SNP Rank p-value Chr. Position Gene 
rs766432 1 2.20E-09 2 60,719,970 BCL11A 
rs2541639 2 1.00E-08 16 205,035 HBM 
rs1427407 3 1.48E-08 2 60,718,043 BCL11A 
rs7861848 4 1.66E-08 9 8,753,534 PTPRD 
rs10172646 5 1.79E-08 2 60,720,757 BCL11A 
rs11886868 6 1.81E-08 2 60,720,246 BCL11A 
rs10195871 7 1.81E-08 2 60,720,589 BCL11A 
rs6732518 8 2.63E-08 2 60,708,597 BCL11A 
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RESULTS UNTIL HBS1L-MYB INTERGENIC REGION MOST SIGNIFICANT SNP (P=2.80E-05) 
Beyond BCL11A and α-globin gene cluster present in genome-wide significant results, selecting SNPs 
with sufficient heterozigosity that demonstrate genome-wide or suggestive significance (until the p-
value of the most significant SNP in the HBS1L-MYB intergenic region, already known for its influence 
on HbF – rs9399137, p=2.80E-05), some further genes can be described (see Table 7).  
Table 7. Results with suggestive significance. 
SNP p-value Chr. position MAF Gene 
rs766432 2.20E-09 2 60,719,970 0.17 BCL11A known HbF levels modifier 
rs2541639 1.00E-08 16 205,035 0.39 HBM α-globin gene cluster 
rs17462275 3.22E-07 14 33,609,861 0.22 NPAS3 
Neuronal PAS domain 
protein 3 
rs10266 3.76E-07 16 107,162 0.4 SNRNP25 (3’UTR) α-globin gene cluster 
rs17525396 6.43E-07 16 145,884 0,20 C160rf35 / NPRL3 α-globin gene cluster 
rs1288829 1.56E-06 3 71,334,477 0,46 FOXP1 
 Forkhead box transcription 
factor family 
rs2562147 1.82E-06 16 114,535 0.48 RHBDF1 α-globin gene cluster 
rs9838898 7.54E-06 3 152,905,655 0.43 
RAP2B 
(downstream) 
(rs6785014 in 
3’UTR: p=3.08E-05) 
Ras family small GTP 
binding protein 
rs1211375 1.23E-05 16 240,280 0.47 LUC7L α-globin gene cluster 
rs11958405 1.39E-05 5 22,247,159 0.49 CDH12 
Cadherin 12, type 2 (N-
cadherin 2) 
rs11121928 1.54E-05 1 12,615,888 0.27 
DHRS3 
(downstream) 
Dehydrogenase/reductase 
(SDR family) member 3 
rs1899398 1.71E-05 3 3,770,669 0.15 SUMF1 Sulfatase modifying factor 1 
rs6843966 1.87E-05 4 6,019,743 0.47 
JAKMIP1 
(downstream) 
Janus kinase and 
microtubule interacting 
protein 1 
rs675046 1.89E-05 11 107,176,219 0.37 
CWF19L2 
(downstream) 
CWF19-like protein 2, cell-
cycle control (S. pombe) 
rs3788504 2.23E-05 22 33,160,397 0.07 SYN3 Synapsin III 
rs7763010 2.37E-05 6 117,762,218 0.13 GOPC 
Golgi associated PDZ and 
coiled-coil motif containing 
rs1362512 2.51E-05 20 15,651,887 0.38 MACROD2 MACRO domain containing 2 
rs9399137 2.80E-05 6 135,419,018 0.19 
HBS1L-MYB 
intergenic region 
known HbF levels modifier 
 
Among these BCL11A, FOXP1, RAP2B, CDH12, SUMF1 and HBS1L-MYB intergenic region are the only 
loci showing coherent and at least partially independent signals, with their most significant marker 
mapping within the gene. Genomic context of these most relevant signals and their effect on 
phenotype severity are described in Figure 8, Figure 9, Figure 10,Figure 11, Figure 12, and Figure 13 
respectively. 
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α-GLOBIN GENE CLUSTER 
Among the results with genome-wide and suggestive significance we find many SNPs within the α-
globin gene cluster, as rs2541639 the most significant one (p=1.00E-08) and rs10266 a non 
synonymous SNP within SNRNP25 (p=3.76E-07), together with (until p=5.0E-04): rs17525396 
(p=6.43E-07), rs2562147 (p=1.28E-06), rs216605 (p=2.71E-06), rs1211375 (p=1.23E-05), rs2157115 
(p=1.00E-04), rs2974771 (p=1.00E-04), rs6600233 (p=2.00E-04) and rs2541675 (p=2.00E-04). 
Interestingly these SNPs highly correlate with α mutation genotype, therefore loosing significance 
when accounting for such mutations in a model, except for rs6600233 (within C16orf35) that keep an 
independent effect on time to first transfusion (p=0.007, exp(β)=1.33) when accounting for top SNPs 
from BCL11A and HS1L-MYB region as well as α mutation genotype and gender, in a Cox proportional 
hazards model. To consider the effect of BCL11A and HBS1L-MYB intergenic region we used the 
following SNPs based on the work by Galarneau et al. (and conducing stepwise conditional analysis as 
well): 
- for BCL11A: rs766432 (that is in full LD with rs4671393), rs10189857, and rs10195871 (the 
best tag for rs7599488); 
- for HBS1L-MYB intergenic region: rs9399137 (even if we had rs4895441 with r2=0.95 with 
rs9402686, as rs9399137 showed a stronger effect in our sample even if we have a lower r2 
between rs9399137 and rs9402686: r2=0.86), rs11759077 (the closest to rs28384513 
showing independent effect through conditional analysis), and rs9376092 and rs6920211  (the 
closest SNPs we had available around ss244317976).25  
Therefore, thanks to the independent effect of rs6600233 we can hypothesize the presence in our 
sample of elements with a significant role in α-globin gene expression, independent from α-globin 
gene deletions or point mutations.  
Genomic context of α-globin gene cluster and effect of α gene deletions are given in Figure 14, while 
some details of outcomes for rs6600233 are given in Figure 15: survival functions for each genotype 
while accounting for gender, BCL11A effect (only rs766432 and rs10189857 remained at last step of 
the Cox proportional hazards model), HBS1L-MYB intergenic region effect and α gene deletions effect, 
showing a significant difference between curves (p=0.007, exp(β)=1.33). 
GENE BASED JOINT TESTING 
To further analyze these results we developed a gene based joint testing approach to identify gene 
associated to the extreme form of the phenotype, using TD versus NTD status. We used a permutation 
based approach as made available in PLINK to identify genes with more than two independent SNPs 
(below r2=0.5 calculated on our sample) at least nominally significant.68 None of these passed a 
multiple testing Bonferroni correction but the first gene was BCL11A, while it is interesting to note 
that the gene FRMPD4, located within Xp22.3, ranked fourth with such approach (while ranking first in 
a case/control TD versus NTD association study, with rs5978532 mapping within the first intron of 
FRMPD4 gene – data not shown). 
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CANDIDATES FROM LITERATURE AND FUNCTIONALLY RELEVANT SNPs 
To complete our analysis of results, we further report the p-values of known candidates from 
literature and functionally relevant SNPs until p=5.00E-04.  
To retrieve known candidates from literature we used PHENOPEDIA and GWAS CATALOG databases 
as well as bibliographic resources from PUBMED, to cross them with our results.90-92 From this 
analysis we can list:  
- BCL11A with rs766432 as the most significant SNP, as previously mentioned (see before and 
Figure 8 for details). 
- HBS1L-MYB intergenic region with rs4895441 as the most significant SNP, as previously 
mentioned (see before and Figure 13 for details). 
- TSHZ2 with rs200603 (p=5.00E-04) at position 51,952,501bp on chromosome 20. This gene, 
that might encode for a transcriptional regulator involved in developmental processes, has 
been reported to be associated with Hb levels in a meta-analysis on erythrocyte phenotypes.93  
- rs17525396 (within C16orf35, in the α-globin gene cluster and containing the α major 
regulatory element) has already been described to be associated to HbA2 and MCH phenotype 
in a Sardinian population in which, however, α gene deletions were not accounted for, while 
this SNP results highly correlated to α gene deletions in our sample.59 
- rs9820070 (p=2.00E-04), an intergenic SNP at position 187,687,074 on chromosome 8. This 
SNP resulted associated with blood urea nitrogen in a recent GWAS on hematological traits in a 
Japanese population.94 
- FLT1 (Fms-related tyrosine kinase 1) with rs12429309 (p=3.00E-04), a receptor for vascular 
endothelial growth factor (VEGF), has tyrosine protein kinase activity that is important for the 
control of cell proliferation and differentiation. This gene has been found to be the most 
associated with HbF percentage levels in a cohort of 137 patients with sickle cell anemia in 
which 280 SNPs were tested for association with HbF response to hydroxyurea treatment.95 
- Regarding the 8q QTL described by Garner et al., we could not investigate such candidate as it 
is supposed to interact with the XmnI-Gγ polymorphism, which is not represented in the 
present sample. For information the most significant signal in an area including 1Mbp before 
D8S538 and 1Mbp after D8S1833 is rs7843301 within SNTG1, a member of the syntrophin 
family specifically expressed in the brain.51-53  
- Regarding the Xp22.3 QTL, no significant association with the time to first transfusion was 
found. However developing a case/control TD versus NTD association study on SNPs a signal 
in the FRMPD4 gene was found with rs5978532 ranking first (see to the previous gene based 
joint testing section also).49 
Regarding SNPs described as functionally relevant, Table 8 list them until p=5.00E-04.  
Table 8. Functionally relevant SNPs. 
SNP p-value Chr. Position Type Gene 
rs10266 3,76E-07 16 107,162 RR - 3’ UTR SNRNP25 
rs216605 2,71E-06 16 113,924 SS - Intronic RHBDF1 
rs17201603 1.00E-04 3 36,898,973 NSC TRANK1 
rs591157 2.00E-04 10 96,954,298 NSC C10orf129 
rs12364019 3.00E-04 11 5,730,343 NMD Transcript TRIM22 
rs3732413 4.00E-04 3 119,133,183 NSC ARHGAP31 
rs2301487 5.00E-04 16 547,297 NSC RAB11FIP3 
[RR = Regulatory Region, NSC = Non Synonymous Coding, SS = Splice Site, NMD = Nonsense Mediated 
Decay]. 
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MODELLING OF PHENOTYPE AMELIORATION 
To summarize and further investigate these results we decided to model the impact of such results on 
β°-thalassemia phenotype amelioration, developing a Cox proportional hazards model for the time to 
first transfusion. We included in the model: gender, BCL11A effect, HBS1L-MYB effect, α gene deletions 
status, and all suggestively significant results from the present study. All markers were treated as 
having an additive effect. 
Regarding BCL11A and HBS1L-MYB effect, as mentioned before, we used the following SNPs based on 
the work by Galarneau et al. and stepwise conditional analysis: 
- for BCL11A: rs766432, rs10189857, and rs10195871; 
- for HBS1L-MYB intergenic region: rs9399137, rs11759077, rs9376092 and rs6920211.25  
We elaborated two Cox proportional hazards models: the first included only known modifiers of 
phenotype severity while the second added to the significant results of the first one, the SNPs with 
suggestive significance. We conducted the analysis in a stepwise manner considering two terms and 
three terms interactions within BCL11A and HBS1L-MYB intergenic region.  
We considered in the first model: gender, BCL11A, HBS1L-MYB intergenic region, α gene deletions 
status and rs6600233, the latter being the previously found independent signal within the α-globin 
gene cluster, a known modifier of β-thalassemia phenotype. Gender did not influence the outcome and 
no interactions were significant between independent SNPs within BCL11A and HBS1L-MYB 
intergenic region. Among SNPs introduced at first step rs10189857, rs10195871 (both within 
BCL11A), rs9376092 and rs6920211 (both within HBS1L-MYB intergenic region) did not show 
significant effect on the outcome, while all others kept independent effects on the time to first 
transfusion with the strongest effect for rs9399137, within HBS1L-MYB intergenic region. Results 
presented in Table 9 demonstrate that BCL11A, HBS1L-MYB intergenic region and α gene deletions 
status are the three main genetic determinants influencing severity of homozygous β°-thalassemia 
phenotype. Furthermore, another independent signal within α-globin gene cluster contribute to the 
phenotype severity.  
The second model added to the first one the following SNPs: rs1899398 (SUMF1 - chr.3), rs1288829 
(FOXP1 - chr.3), rs11958405 (CDH12 - chr.5), rs7763010 (GOPC - chr.6), rs17462275 (NPAS3 - 
chr.14), rs1362512 (MACROD2 - chr.20), rs3788504 (SYN3 - chr.22), rs11121928 (DHRS3 - chr.1), 
rs9838898 (RAP2B - chr.3), rs6843966 (JAKMIP1 - chr.4) and rs675046 (CWF19L2 - chr.11). All SNPs 
remained to final step of the model except rs1362512 and rs9838898. As we can see in Table 9, 
elements introduced in the first block did not change much when adding the suggestive results of the 
study. Without a replication of the suggestive results from the GWAS, the only interest of the second 
model is to establish the independency of effects of these SNPs. Figure 16 shows the survival function 
at the mean of covariates for model 2. 
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Table 9. Determinants of phenotype amelioration upon Cox proportional hazards model for time to 
first transfusion. 
 
β 
Std. 
Err. 
Wald 
stat. 
df p-value exp(β) 
exp(β) 
95% IC 
Inf. Sup. 
Model 
1 
rs766432 [BCL11A - chr.2] -0.766 0.147 27.04 1 <0.0001 0.46 0.35 0.62 
rs9399137 [HBS1L-MYB - chr.6] 0.913 0.190 23.03 1 <0.0001 2.49 1.72 3.62 
α gene deletions [chr.16] 0.479 0.112 18.12 1 <0.0001 1.61 1.29 2.01 
rs6600233 [C16orf35 - chr.16] 0.267 0.105 6.41 1 0.0114 1.31 1.06 1.61 
rs11759077 [HBS1L-MYB - chr.6] -0.414 0.169 6.01 1 0.0142 0.66 0.48 0.92 
Model 
2 
rs9399137 [HBS1L-MYB - chr.6] 0.981 0.195 25.24 1 <0.0001 2.67 1.82 3.91 
rs7763010 [GOPC - chr.6] 0.671 0.151 19.75 1 <0.0001 1.96 1.45 2.63 
rs675046 [CWF19L2 - chr.11] -0.417 0.099 17.59 1 <0.0001 0.66 0.54 0.80 
rs11121928 [DHRS3 - chr.1] 0.492 0.121 16.41 1 0.0001 1.64 1.29 2.08 
α gene deletions [chr.16] 0.462 0.118 15.20 1 0.0001 1.59 1.26 2.00 
rs766432 [BCL11A - chr.2] -0.570 0.156 13.38 1 0.0003 0.57 0.42 0.77 
rs3788504 [SYN3 - chr.22] 0.723 0.204 12.57 1 0.0004 2.06 1.38 3.07 
rs11759077 [HBS1L-MYB - chr.6] -0.579 0.176 10.83 1 0.0010 0.56 0.40 0.79 
rs11958405 [CDH12 - chr.5] -0.311 0.100 9.71 1 0.0018 0.73 0.60 0.89 
rs17462275 [NPAS3 - chr.14] -0.295 0.114 6.74 1 0.0094 0.74 0.60 0.93 
rs1288829 [FOXP1 - chr.3] -0.253 0.106 5.65 1 0.0174 0.78 0.63 0.96 
rs6843966 [JAKMIP1 - chr.4] -0.252 0.108 5.48 1 0.0193 0.78 0.63 0.96 
rs1899398 [SUMF1 - chr.3] -0.291 0.144 4.07 1 0.0436 0.75 0.56 0.99 
rs6600233 [C16orf35 - chr.16] 0.211 0.113 3.50 1 0.0613 1.24 0.99 1.54 
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CONCLUSIONS 
Without treatment, children with thalassemia major have severe failure to thrive and shortened life 
expectancy. Furthermore, even if treatment with a regular transfusion program and chelation therapy 
extends life expectancy into the third to fifth decade, these individuals are at risk for iron overload 
secondary to increased intestinal absorption of iron as a result of ineffective erythropoiesis. This 
excess is the cause of many serious complications affecting mostly liver, heart and endocrine glands, 
that can be fatal to patients.  
Much can still be done to improve life-expectancy and quality of life of these patients and some of it 
probably lies in better understanding of phenotypic severity variations. A lot of work has been done in 
the recent years to explain HbF production variations, an important modulator of β-thalassemia 
phenotype severity. However, a great part of phenotypic variation has still to be clearly understood 
and its eventual genetic determinants to be unrevealed.  
To our knowledge, this study is the first whole genome association scan for modifiers of homozygous 
β°-thalassemia phenotype severity (through survival analysis of time to first transfusion), as well as 
the first association study of rare CNVs with HbF levels (through NTD patients characterized by the 
presence of nearly 100% of HbF).  
The results from the present study demonstrate that BCL11A, HBS1L-MYB intergenic region and α-
globin gene deletions are major determinants of homozygous β°-thalassemia phenotype severity, 
using a genome-wide approach and an accurate phenotype definition on a particularly homogeneous 
population, therefore bringing detailed and new information to the previous works dealing with 
genetic determinants of β-thalassemia phenotype severity.61,96,97 These results are coherent with 
findings on genetic determinants of disease severity in β°-thalassemia/hemoglobin E Thai patients 
from Nuinoon et al. as this study found only BCL11A and HBS1L-MYB, outside of the β-globin gene 
cluster, to be significantly associated with disease severity score.61 Regarding the other GWAS 
conducted by Sherva et al. on the same population and phenotype (severity score was defined 
differently however), only the HBS1L-MYB intergenic region was found in common with the present 
study.96 
Furthermore, we show that the severity of β°-thalassemia phenotype might be influenced by a rare 
CNV showing duplication on chromosome 4 spanning from 165.4 to 166.5 Mbp that was found in two 
NTD patients and no TD patient. The two patients presenting such CNV are negative for the BCL11A 
protective allele (according to rs766432) while one is positive for the HBS1L-MYB protective allele 
(according to rs9399137), leaving unexplained at least for one patient his NTD status (we do not 
consider α-globin gene deletions as the case/control study applied for CNV association investigates 
HbF levels). The CNV crosses three genes, namely TRIM60, TRIM61 and KLHL2. The two first ones 
encode for proteins that contain a RING finger domain, a motif present in a variety of functionally 
distinct proteins and known to be involved in protein-protein and protein-DNA interactions. KLHL2 is 
a member of the kelch family of protein, which members associate with the actin cytoskeleton and 
regulate process length, but KLHL2 is also suspected to be a tumor growth promoter. Furthermore, in 
addition to the genes crossed, the microRNA MIR578 results to be produced in this region. MIR578 has 
BCL11B among its targets, a gene which function is still unknown but showing a high homology with 
BCL11A. It could therefore present the same sequence as the one in BCL11A gene, responsible for the 
formation of a repressor complex.43 
We also show that a SNP within the α-globin gene cluster determine an effect on phenotype 
independent from α-globin gene deletions or point mutations. Thanks to this SNP we can hypothesize 
the presence in our sample of elements with a significant role in α-globin gene expression, 
independent from α-globin gene deletions or point mutations. This could involve deletions of the α 
major regulatory element (α-MRE) as it lies 10kbp downstream from rs6600233, or even a mechanism 
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similar to the creation of a new promoter-like as described by De Gobbi et al.98,99 Such result is 
sustained by recent studies demonstrating that α-MRE polymorphisms are correlated with variations 
in gene expression, although the SNPs constituting the six known different haplotypes are outside the 
binding sites for nuclear factors.100  
Finally, the present study also gives some elements about twelve other markers that could be involved 
in homozygous β°-thalassemia phenotype severity, of which four present a reliable signal within a 
gene and three also show an independent effect when modeled with other determinants of β-
thalassemia phenotype severity (the four genes being FOXP1, CDH12, SUMF1 and RAP2B). These 
genes are not significant at genome-wide level but their function is relevant to β-thalassemia 
phenotype severity.  
FOXP1 gene (forkhead box P1) belongs to the subfamily P of the forkhead box transcription factor 
family. Forkhead box transcription factors play important roles in the regulation of tissue and cell 
type-specific gene transcription during both development and adulthood. This ubiquitously expressed 
gene is implicated in malignancies and plays an important role in cardiac and lung development, B-cell 
development and macrophage differentiation.  
CDH12 gene (cadherin 12, type 2 - N-cadherin 2) encodes a type II classical cadherin from the cadherin 
superfamily of integral membrane proteins that mediate calcium-dependent cell-cell adhesion. This 
particular cadherin appears to be expressed specifically in the brain but its mRNA is present in several 
additional tissues, suggesting that there is posttranscriptional control of this gene's expression.101 
Mutations and loss of expression of cadherins have been implicated in the progression of some 
malignant tumors, suggesting that cadherins including CDH12 may act as tumor-metastasis 
suppressor genes.102,103  
SUMF1 gene (sulfatase modifying factor 1) encodes an enzyme that catalyzes the hydrolysis of sulfate 
esters by oxidizing a cysteine residue in the substrate sulfatase to an active site 3-oxoalanine residue, 
which is also known as C-alpha-formylglycine. Mutations in this gene determine cellular dysfunction 
by blocking autophagic protein clearance.104 SUMF1 is therefore correlated to the unfolded protein 
response (UPR) as the autophagic process is required to counterbalance the expansion of endoplasmic 
reticulum during the UPR.105-108 And prolonged UPR activation induces apoptosis, so that SUMF1 could 
be correlated to erythroptosis.109 Furthermore SUMF1 seems to control hematopoietic stem 
progenitor cells differentiation and hematopoietic lineage development through FGF and Wnt 
signaling.110 
RAP2B encodes for a Ras family small GTP binding protein expressed in human red blood cells where 
it might have a role in membrane shedding, while the loss of phosphatidylserine asymmetry of the 
erythrocyte membrane which plays key role in early clearance of erythrocytes from circulation in β°-
thalassemia, seems to be mediated by membrane vesiculation.111,112 Furthermore RAP2B is also 
believed to interact with platelet cytoskeleton by direct binding to actin filament, while the existence 
of a chronic hypercoagulable state involving significant changes in platelet membrane protein 
fractions is recognized in β thalassemic patients.113,114 Changes in protein fractions of both 
erythrocytes and platelets correlate with severity of clinical manifestation of the disease.115 
These results need to be further investigated, eventually through sequencing of the α-MRE, laboratory 
validation of the CNV, and replication of the suggestively significant SNPs in an independent cohort of 
β thalassemic patients. Hopefully the duplication on chromosome 4 could bring new insights on HbF 
production mechanisms while some of the most significant SNPs might uncover aspects of the 
unexplained phenotypic variability of β-thalassemia, and make a step towards better life for patients.  
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FIGURES 
 
Figure 1. Identity by state of samples. 
[back to text] 
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Figure 2. Percentage of overlap between CNVs collapsed together when identifying consensual CNVs 
between segmentation algorithms. 
[back to text] 
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PENNCNV (3,934 CNVs) 
74% of consensual CNVs 
QUANTISNP (6,507 CNVs) 
34% of consensual CNVs 
GTC (9,490 CNVs) 
35% of CNVs consensual with at least one 
other segmentation process 
Figure 3. Consensual CNVs between segmentation algorithms. 
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Figure 4. Quantile-quantile plot of observed associations compared with the expectations under no 
association. 
[back to text] 
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Figure 5. Intensity signals of two NTD samples showing duplication in a region spanning from 165.4 to 
166.5Mb on chromosome 4. 
[back to text] 
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Figure 6. Intensity signals of NTD samples showing duplication in a region spanning from 165.4 to 
166.5Mb on chromosome 4, upon different segmentation algorithms. 
[back to text] 
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Figure 7. Manhattan plot. 
[back to text] 
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Figure 8. BCL11A gene and effect of its respective most significant SNP on time to first transfusion. 
[back to text] 
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Figure 9. FOXP1 gene and effect of its respective most significant SNP on time to first transfusion. 
[back to text] 
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Figure 10. RAP2B gene and effect of its respective most significant SNP on time to first transfusion. 
[back to text] 
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Figure 11. CDH12 gene and effect of its respective most significant SNP on time to first transfusion. 
[back to text] 
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Figure 12. SUMF1 gene and effect of its respective most significant SNP on time to first transfusion. 
[back to text] 
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Figure 13. HBS1L-MYB intergenic region and effect of its respective most significant SNP on time to 
first transfusion. 
[back to text] 
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Figure 14. α-globin gene cluster and effect of α gene deletions on time to first transfusion. 
[back to text] 
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Figure 15. Survival functions for rs6600233 while accounting for gender, BCL11A, HBS1L-MYB 
intergenic region and α gene deletions effects on time to first transfusion, showing a significant 
difference between curves (p=0.007, exp(β)=1.33).  
[back to text] 
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Figure 16. Survival function at the mean of covariates while accounting for effects on time to first 
transfusion of gender, BCL11A, HBS1L-MYB intergenic region, α gene deletions and suggestively 
significant results from the present study. 
[back to text] 
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